Ihc to dd retroperitoneal carcinoma
Reading File
IHC to differentiate (DD = differential diagnosis) retroperitoneal carcinoma involves distinguishing between several tumor types that can present as retroperitoneal masses. Let me search the library for detailed IHC panels.
Searching sources...
Finding Sources
Finding Sources
Searching the Web
IHC panel retroperitoneal carcinoma differential diagnosis immunohistochemistry markers
Finding Sources
Finding Sources
Reading Web Page
https://pmc.ncbi.nlm.nih.gov/articles/PMC5923363
Here is a comprehensive guide to IHC for differential diagnosis of retroperitoneal carcinoma.
IHC Panel for Retroperitoneal Carcinoma - Differential Diagnosis
Retroperitoneal masses encompass a wide range of tumor types. The diagnostic approach uses a stepwise IHC strategy.
Step 1: Establish Lineage (First-Line Panel)
Before determining the primary site, confirm whether the tumor is a carcinoma, sarcoma, lymphoma, or melanoma:
| Marker | Positive in |
|---|---|
| Pan-CK (AE1/AE3, CAM5.2) | Carcinoma, mesothelioma |
| CD45 (LCA) | Lymphoma |
| S100 / SOX10 | Melanoma, nerve sheath tumors |
| Vimentin | Sarcoma, RCC, adrenocortical |
| Desmin / SMA | Smooth/skeletal muscle sarcoma |
A vimentin-negative tumor is unlikely to be a sarcoma, lymphoma, or melanoma.
Step 2: CK7 / CK20 Profile - The Backbone of Carcinoma Subtyping
| Profile | Common Primary Sites |
|---|---|
| CK7+ / CK20- | Lung, breast, ovary, endometrium, thyroid, cervix, pancreas, biliary |
| CK7+ / CK20+ | Urothelial, pancreas, mucinous ovarian, gastric, cholangiocarcinoma |
| CK7- / CK20+ | Colorectal, Merkel cell |
| CK7- / CK20- | RCC, adrenocortical, HCC, prostate, squamous (some), mesothelioma |
Step 3: Organ-Specific IHC Markers for Retroperitoneal Tumors
Renal Cell Carcinoma (RCC)
The most common retroperitoneal primary carcinoma.
| Marker | Result | Notes |
|---|---|---|
| PAX8 | + | Highly sensitive for RCC; also + in thyroid, Mullerian |
| pVHL | + | Highly sensitive + specific for clear cell RCC |
| CD10 | + | Sensitive but not specific |
| RCC marker (RCCma) | + | Less sensitive in high-grade |
| CAIX (carbonic anhydrase IX) | + | Strong in clear cell RCC |
| CK7 | - (clear cell), + (papillary) | |
| CK20 | - | |
| Vimentin | + |
Panel recommended: PAX8 + pVHL + RCCma + CAIX. Single-marker approach discouraged.
Adrenocortical Carcinoma (ACC)
Critical mimic of RCC in the retroperitoneum.
| Marker | Result |
|---|---|
| Melan-A (A103) | + |
| Inhibin-alpha | + |
| SF-1 (steroidogenic factor-1) | + (most specific) |
| Synaptophysin | +/- |
| Pan-CK | - or focal |
| PAX8 | - |
| RCC marker | - |
| Chromogranin | - |
Key: Inhibin+ / PAX8- strongly favors ACC over RCC.
Retroperitoneal Germ Cell Tumor (GCT)
Common in young males as retroperitoneal primary.
| Marker | Result | Tumor type |
|---|---|---|
| PLAP | + | Seminoma / NSGCT |
| OCT4 (OCT3/4) | + | Seminoma, embryonal carcinoma |
| SALL4 | + | All GCTs (highly sensitive) |
| AFP | + | Yolk sac tumor |
| hCG / beta-hCG | + | Choriocarcinoma |
| CD30 | + | Embryonal carcinoma |
| D2-40 | + | Seminoma |
| Pan-CK | Variable (+ in embryonal, - in seminoma) |
Hepatocellular Carcinoma (HCC) - Retroperitoneal metastasis
| Marker | Result |
|---|---|
| Arginase-1 (ARG1) | + (most specific) |
| HepPar-1 (Hepar1) | + |
| Canalicular pCEA / CD10 / CD13 | + (canalicular pattern) |
| GPC3 (glypican-3) | + |
| AFP | + (less sensitive) |
| CK7 | - |
| CK20 | - |
| PAX8 | - |
Neuroendocrine Carcinoma (NEC) - including paraganglioma/pheo
| Marker | Result |
|---|---|
| Chromogranin A | + |
| Synaptophysin | + |
| CD56 | + |
| TTF1 | + (small cell lung origin) |
| Ki-67 | Used for grading (G1 <3%, G2 3-20%, G3 >20%) |
| GATA3 | + in paraganglioma |
| S100 (sustentacular cells) | + in paraganglioma |
| Pan-CK | + (carcinoma); - (paraganglioma) |
Paraganglioma: Chromogranin+ / Synaptophysin+ / CK- - distinguish from NEC which is CK+.
Mesothelioma (Peritoneal) - vs retroperitoneal adenocarcinoma
| Positive (Mesothelial) | Negative (Carcinoma favored) |
|---|---|
| Calretinin | MOC-31 |
| WT1 (nuclear) | Ber-EP4 |
| D2-40 (podoplanin) | BG-8 (Lewisy) |
| CK5/6 | B72.3 |
| Thrombomodulin | CA19-9 |
International Mesothelioma Interest Group recommends: 2 positive mesothelial markers + 2 negative (carcinoma) markers.
Retroperitoneal Liposarcoma (Sarcoma mimic)
| Marker | Result |
|---|---|
| MDM2 | + (amplified) |
| CDK4 | + |
| HMGA2 | + |
| Pan-CK | - |
| S100 | +/- (well-differentiated) |
MDM2/CDK4 co-amplification by FISH confirms dedifferentiated liposarcoma.
Quick-Reference Summary Table
| Tumor | Key Positive Markers | Key Negative Markers |
|---|---|---|
| RCC (clear cell) | PAX8, pVHL, CAIX, CD10, Vimentin | CK7, CK20, Inhibin |
| Adrenocortical Ca | Inhibin, Melan-A, SF-1, Synaptophysin | PAX8, Pan-CK, Chromogranin |
| Retroperitoneal GCT | SALL4, OCT4, PLAP, AFP/hCG (subtypes) | - |
| HCC (met) | ARG1, HepPar1, GPC3, canalicular CEA | CK7, CK20, PAX8 |
| NEC / Paraganglioma | Chromogranin, Synaptophysin, CD56 | CK (paraganglioma) |
| Peritoneal Mesothelioma | Calretinin, WT1, D2-40, CK5/6 | BerEP4, MOC-31, B72.3 |
| Liposarcoma | MDM2, CDK4, Vimentin | Pan-CK |
| Colorectal met | CK20, CDX2, SATB2 | CK7 |
| Ovarian serous | PAX8, WT1, ER, CA-125 | - |
| Urothelial Ca | GATA3, CK7, CK20, p63, uroplakin | - |
Practical Diagnostic Algorithm
Retroperitoneal mass on biopsy
|
v
Pan-CK + CD45 + S100/SOX10 + Vimentin
|
CK positive? --> CARCINOMA / MESOTHELIOMA
|
CK7 / CK20 profile
|
CK7-/CK20- --> RCC, ACC, HCC, Prostate, GCT
CK7+/CK20- --> Ovarian, Lung, Breast, Endometrial
CK7-/CK20+ --> Colorectal (CDX2, SATB2)
CK7+/CK20+ --> Urothelial, Mucinous ovarian, Pancreas
Key practical tips:
- In a young male: always include GCT markers (SALL4, OCT4, PLAP) first
- RCC vs ACC is a common pitfall: use PAX8 (RCC+, ACC-) and Inhibin (ACC+, RCC-)
- Paraganglioma vs NEC: CK separates them (NEC+, paraganglioma-)
- Always use a panel, never a single marker
This is a shared conversation. Sign in to Orris to start your own chat.